Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma-2

By flow cytometric analysis showing populations of (a) live cells, (b) necrotic cells, and (c) apoptotic cells. (B) Viability of Rec-1 and Jeko-1 cells treated with either 20 nM bortezomib or 0.3 mM POH for 24 hours relative to controls exposed only to vehicle shown as mean ± 1SD from triplicate wells. The unpaired -test between viability of Jeko-1 and Rec-1 cells treated with bortezomib * = 0.002 or POH **= 0.0001 were both statistically significant (< 0.01). (C) EMSAs of whole cell extracts from 1.0 × 10cells treated with 20 nM bortezomib or their respective median-effect dose of POH for 4 hours probed with P-radiolabeled oligonucleotide containing either the consensus NF-κB or Oct-1 binding sequence. Fold activity refers to NF-κB binding normalized to Oct-1 binding in each condition.<p><b>Copyright information:</b></p><p>Taken from "Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma"</p><p>http://www.molecular-cancer.com/content/7/1/40</p><p>Molecular Cancer 2008;7():40-40.</p><p>Published online 19 May 2008</p><p>PMCID:PMC2408930.</p><p></p>